<DOC>
	<DOCNO>NCT02254811</DOCNO>
	<brief_summary>Delivery FMT upper route , include gastroscopy , nasogastric/ nasojejunal tube , low route , include retention enema , sigmoidoscopy , colonoscopy utilized successfully . Endoscopic delivery require significant health care utilization associate cost . Therefore , extremely desirable FMT infuse non invasive modality , would significantly reduce patient discomfort , procedure related risk health care cost , offer similar efficacy colonoscopic delivery range 90 % .</brief_summary>
	<brief_title>FMT Delivered Capsule Versus Colonoscopy Recurrent C. Diff</brief_title>
	<detailed_description>Patients minimum 3 episode Clostridium difficile within 6 month randomize 1:1 receive FMT either colonoscopy capsule . Pts assess 1 week , 2 week , 1 mon , 3 mon , 6 mon 1 year post FMT . Stool , urine blood sample collect . Medical cost previous treatment collect well pt perspective QoL .</detailed_description>
	<mesh_term>Enterocolitis</mesh_term>
	<criteria>1 . Age &gt; 18 &lt; 90 year time Screening . 2 . Diagnosis least 3 episode recurrent CDI , episode define presence diarrhea ( &gt; 3 unformed stools/24 hour ) associate positive stool Clostridium difficle toxin , occur within 3 month . 3 . CDI infection symptomatic control &lt; 3 loose/unformed BM 's per 24 h period least 2 consecutive day procedure . 4 . Those ability provide inform consent . 1 . Those complicated CDI , define white blood cell &gt; 35 &lt; 0.5 x 109/L , significant abdominal pain distension evidence toxic megacolon pseudomembranous colitis , hypotension define systolic blood pressure &lt; 90 mmHg unresponsive fluid resuscitation , end organ failure , require intensive care unit admission . 2 . Those chronic diarrheal illness , irritable bowel syndrome inflammatory bowel disease unless remission least 3 month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>